Literature DB >> 4631348

Therapeutic trial of immunosuppressive agents in multiple sclerosis.

J W Neumann, D K Ziegler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4631348     DOI: 10.1212/wnl.22.12.1268

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

1.  Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.

Authors:  E M Lance; M Kremer; J Abbosh; V E Jones; S Knight; P B Medawar
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

Review 2.  Immunopathological comparisons between experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  I R Mackay; P R Carnegie; A S Coates
Journal:  Clin Exp Immunol       Date:  1973-12       Impact factor: 4.330

3.  Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.

Authors:  R D Currier; A F Haerer; E F Meydrech
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

Review 4.  Role of immunosuppressive therapy for the treatment of multiple sclerosis.

Authors:  James M Stankiewicz; Hadar Kolb; Arnon Karni; Howard L Weiner
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

5.  Clinical use of immunosuppressive drugs: part II.

Authors:  N L Gerber; A D Steinberg
Journal:  Drugs       Date:  1976       Impact factor: 9.546

6.  Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.

Authors:  R E Gonsette; L Demonty; P Delmotte
Journal:  J Neurol       Date:  1977-02-17       Impact factor: 4.849

7.  A narrative review of psoriasis and multiple sclerosis: links and risks.

Authors:  Annika S Silfvast-Kaiser; Katie B Homan; Bobbak Mansouri
Journal:  Psoriasis (Auckl)       Date:  2019-08-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.